Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers June 23, 2017
Pharmacy Choice - News - Pharmaceutical Development - June 23, 2017

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

6/23/17 - 22nd Century Receives Guidance from FDA on Phase III Clinical Trials [Tehran Times (Iran)]
22nd Century Group, Inc., a plant biotechnology company that is a leader in tobacco harm reduction, announced today that on June 20, 2017, the Company and its wholly owned subsidiary, Heracles Pharmaceuticals, participated in a meeting with the multi-discipline review team in the Division of Anesthesia, Analgesia, and Addiction Products at the Cent
6/23/17 - AbbVie Announces Pivotal Phase 2 Trial Evaluating VENCLYXTO? (venetoclax) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) with 17p Deletion to be Presented at 22nd European Hematology Association (EHA) Annual Congress
AbbVie, a global biopharmaceutical company, today announced the presentation of results from the pivotal Phase 2 study of VENCLYXTO?, a first-in-class oral B-cell lymphoma-2 inhibitor. VENCLYXTO monotherapy was granted conditional marketing authorization in the EU for the treatment of CLL in the presence of 17 p deletion or TP53 mutation in adu
6/23/17 - AbbVie Receives CHMP Positive Opinion for MAVIRET? (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)
AbbVie, a global biopharmaceutical company, today announced that the European Committee for Medicinal Products for Human Use of the European Medicines Agency has granted a positive opinion recommending marketing authorization of MAVIRET?, an investigational, pan-genotypic treatment for adults with chronic hepatitis C virus infection.
6/23/17 - Acceleron Provides Updated Results from Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes at the 22nd Congress of the European Hematology Association
Acceleron Pharma Inc., a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapeutics to treat serious and rare diseases, today announced preliminary results from the ongoing Phase 2 studies of luspatercept in patients with lower-risk myelodysplastic syndromes at the 22 nd Congress
6/23/17 - Acceleron Provides Updated Results from Phase 2 Studies of Luspatercept in Beta-Thalassemia at the 22nd Congress of the European Hematology Association
Acceleron Pharma Inc., a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapeutics to treat serious and rare diseases, today announced preliminary results from the ongoing Phase 2 study of luspatercept in patients with beta-thalassemia during an oral presentation at the 22 nd...
6/23/17 - Akari Therapeutics to Present Data from Phase 2 PNH Trial of Coversin at the 22nd Congress of the European Hematology Association
Akari Therapeutics, a clinical-stage biopharmaceutical company, is presenting a poster today at the 22nd Congress of the European Hematology Association in Madrid, Spain containing data for the four patients, to date, who have completed its ongoing Phase 2 trial of Coversin in paroxysmal nocturnal hemoglobinuria. Coversin is a second-generation..
6/23/17 - Alexion Receives Positive CHMP Opinion for Soliris (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG) in the European Union
Alexion Pharmaceuticals, Inc. announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion to extend the current therapeutic indication for Soliris to include the treatment of refractory generalized myasthenia gravis in patients who are anti-acetylcholine receptor...
6/23/17 - Amgen Receives Positive CHMP Opinion To Expand Use Of Mimpara (cinacalcet) For The Treatment Of Secondary Hyperparathyroidism In Certain Children With End-Stage Renal Disease On Dialysis
THOUSAND OAKS, Calif., June 23, 2017/ PRNewswire/ Amgen today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the Marketing Authorization of a pediatric formulation of Mimpara . The CHMP positive opinion will now be reviewed by the European Commission, which h
6/23/17 - Anti-tumor Activity Observed in Phase 1 Trial of Novel P53-Targeting Drug ALRN-6924
By a News Reporter-Staff News Editor at Drug Week Aileron Therapeutics, a clinical-stage biopharmaceutical company developing a novel class of therapeutics called stapled peptides, announced safety and clinical activity data, including complete responses, partial responses and evidence of stable disease, from its Phase 1, multi-center trial with.
6/23/17 - AP Top Health News at 11:20 a.m. EDT
GOP's challenge: finding votes for Senate health care bill Governors wary of Medicaid cost shift in Senate health bill Hints of some steps that may boost brain health in old age The Latest: Arrests at Capitol of health bill protesters FDA approves quicker-to-administer drug for blood cancers Sri Lankan doctors strike to demand university's closure
6/23/17 - AP Top Health News at 11:32 a.m. EDT
GOP's challenge: finding votes for Senate health care bill Governors wary of Medicaid cost shift in Senate health bill Prosecutors seek 35- year term in deadly meningitis outbreak Hints of some steps that may boost brain health in old age The Latest: Arrests at Capitol of health bill protesters FDA approves quicker-to-administer drug for blood canc
6/23/17 - AP Top Health News at 12:29 a.m. EDT
Governors wary of Medicaid cost shift in Senate health bill Hints of some steps that may boost brain health in old age Senate GOP unveils' Obamacare' overhaul, but not all aboard The Latest: Arrests at Capitol of health bill protesters How the Senate health bill compares to House,' Obamacare' FDA approves quicker-to-administer drug for blood cancer
6/23/17 - AP Top Health News at 3:45 a.m. EDT
McConnell faces hunt for GOP votes for Senate health bill Sri Lankan doctors on strike to demand university's closure Governors wary of Medicaid cost shift in Senate health bill Hints of some steps that may boost brain health in old age The Latest: Arrests at Capitol of health bill protesters FDA approves quicker-to-administer drug for blood cancer
6/23/17 - AP Top Health News at 8:02 a.m. EDT
GOP's challenge: finding votes for Senate health care bill Sri Lankan doctors on strike to demand university's closure Governors wary of Medicaid cost shift in Senate health bill Hints of some steps that may boost brain health in old age The Latest: Arrests at Capitol of health bill protesters FDA approves quicker-to-administer drug for blood cance
6/23/17 - Biogen's IMRALDI, an Adalimumab Biosimilar Candidate Referencing Humira, Granted Positive Opinion by Committee for Medicinal Products for Human Use
The Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for IMRALDI , an adalimumab biosimilar candidate referencing Humira . 1 The positive opinion will now be referred to the European Commission, which grants marketing authorization for medicines in the European Union. Today, the anti-
6/23/17 - Bipartisan Group of Members of Senate Judiciary Committee Urge FDA Commissioner to Address Abuses in Regulatory Process That Delay Competition, Increase Prescription Drug Costs
Commissioner Gottlieb recently stated that the FDA will take measures to curb anticompetitive abuses of its regulatory process for the approval of generic drugs. In their letter, the senators advocate for their legislative solution and ask Commissioner Gottlieb to detail the regulatory actions the FDA can and cannot take to address strategies that.
6/23/17 - Cara Receives Breakthrough Therapy Designation from FDA for I.V. CR845 for the Treatment of Chronic Kidney Disease-Associated Pruritus in Hemodialysis Patients
Cara Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to I.V.
6/23/17 - Cardiome Pharma Corp. Announces Voting Results
-Cardiome Pharma Corp. today announced the results of voting at its 2017 Annual General and Special Meeting of Shareholders held on June 20, 2017. About Cardiome Pharma Corp. Cardiome Pharma Corp. is a specialty pharmaceutical company dedicated to the development and commercialization of innovative therapies that will improve the quality of life an
6/23/17 - Cardiovascular Outcomes Trial of Anti-Obesity Agent Lorcaserin to Continue Based on Recommendation of Independent Data Monitoring Committee After Completion of Interim Safety Analysis
This Phase IIIb/IV clinical study, comprised of 12,000 patients, is being conducted over a 5- year period in partnership with the Thrombolysis in Myocardial Infarction Study Group and is intended to address the post-marketing requirement from the U.S. Food and Drug Administration to evaluate the long-term cardiovascular safety of lorcaserin.
6/23/17 - CARsgen Therapeutics Presented at the 2017 BIO International Convention
SAN DIEGO, June 23, 2017/ PRNewswire/ CARsgen Therapeutics, a global biotech start-up focused on developing chimeric antigen receptor T-cell therapies for solid tumors, presented at the 2017 BIO International Convention this week in San Diego, CA.. For its progress on cancer immunotherapy, typically for CAR-T therapies to treat solid tumors, CARs
6/23/17 - Catabasis Pharmaceuticals to Present Results from the MoveDMD Trial of Edasalonexent (CAT-1004) at the 2017 PPMD Annual Connect Conference
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced that it will present data from Part A and Part B of the MoveDMD trial of edasalonexent in an oral presentation at the upcoming 2017 Parent Project Muscular Dystrophy Annual Connect Conference to be held June 29 July 2, 2017, in Chicago, IL, at the Chicag
6/23/17 - Cause of Neuropsychiatric Ills Common to Lupus Seen in Study, Potential Treatment Raised [Sport360]
Neuropsychiatric symptoms in people with systemic lupus erythematosus may be caused by increased levels of the inflammatory molecule interferon-alpha in their brains, according to a study published in the journal Nature. But the research team from Boston Childrens Hospital also found increased interferon activity in patients brains, suggesting the.
6/23/17 - Deep Brain Stimulation Shows Promise for Chronic Pain [Sport360]
Deep brain stimulation shows promise for chronic painthats according to results from the first prospective, randomized, controlled trial of DBS for neuropathic pain. For the study, researchers from the Cleveland Clinic enrolled ten patients with longstanding post-stroke pain syndrome. Post-stroke pain syndrome was chosen because it is associated wi
6/23/17 - Enanta Announces that AbbVie Receives CHMP Positive Opinion for MAVIRET? (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)
Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that the European Committee for Medicinal Products for Human Use of the European Medicines Agency has granted AbbVie a positive opinion recommending marketing...
6/23/17 - Enrollment in Phase 1/2a Study of IONIS-HTT Rx in Patients with Huntington`s Disease Completed and Open-Label Extension Study to Open in 2H 2017 [Syrian Arab News Agency]
Ionis Pharmaceuticals, Inc. today announced the completion of enrollment in the Phase 1/ 2 a randomized, placebo-controlled, dose escalation study of IONIS-HTTRx in patients with Huntington`s disease. Roche, Ionis` partner for this drug, continues to advance and support the program. Upon completion and full analysis of this study, the next step for
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Telepharmacy- Remote Delivery of Pharmacy Services
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415